Methylprednisolone

Essential medicine status ✓

EMLc | ATC codes: H02AB04

Indication	Lymphoid leukaemia, not elsewhere classified ICD11 code: 2C03.3
INN	Methylprednisolone
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc) ; 40 mg per mL in 5 mL multi-dose vial (as sodium succinate) (EMLc) ; 80 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc)
EML status history	First added in 2011 (TRS 965) Changed in 2015 (TRS 994)
Sex	All
Age	Children (1 month - 12 years)
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Methylprednisolone
DrugBank	Methylprednisolone

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methylprednisolone injection on the complementary list of the EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.

Expert Committee report